Hansa Biopharma provides business update ahead of the JP Morgan Global Healthcare Conference
• Responses to Day 120 questions submitted for EMA MAA of imlifidase• First patients dosed in GBS trial; Enrollment in anti-GBM trial near completion• Solid year-end cash positionLund, Sweden January 12, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2019 and preliminary, unaudited key financials for its financial year 2019. The company will be participating in the JP Morgan Global Healthcare Conference in San Francisco from January 13 to 16, 2020. 2019